Baseline JAK phosphorylation profile of peripheral blood leukocytes, studied by whole blood phosphospecific flow cytometry, is associated with 1-year treatment response in early rheumatoid arthritis

Show full item record



Permalink

http://hdl.handle.net/10138/189049

Citation

Kuuliala , K , Kuuliala , A , Koivuniemi , R , Kautiainen , H , Repo , H & Leirisalo-Repo , M 2017 , ' Baseline JAK phosphorylation profile of peripheral blood leukocytes, studied by whole blood phosphospecific flow cytometry, is associated with 1-year treatment response in early rheumatoid arthritis ' , Arthritis research & therapy , vol. 19 , 75 . https://doi.org/10.1186/s13075-017-1278-0

Title: Baseline JAK phosphorylation profile of peripheral blood leukocytes, studied by whole blood phosphospecific flow cytometry, is associated with 1-year treatment response in early rheumatoid arthritis
Author: Kuuliala, Krista; Kuuliala, Antti; Koivuniemi, Riitta; Kautiainen, Hannu; Repo, Heikki; Leirisalo-Repo, Marjatta
Other contributor: University of Helsinki, Medicum
University of Helsinki, Department of Bacteriology and Immunology
University of Helsinki, Department of Medicine
University of Helsinki, Department of General Practice and Primary Health Care
University of Helsinki, Department of Bacteriology and Immunology
University of Helsinki, Clinicum







Date: 2017-04-11
Language: eng
Number of pages: 8
Belongs to series: Arthritis research & therapy
ISSN: 1478-6354
DOI: https://doi.org/10.1186/s13075-017-1278-0
URI: http://hdl.handle.net/10138/189049
Abstract: Background: We found recently that baseline signal transducer and activator of transcription 3 phosphorylation in peripheral blood CD4(+) T cells of patients with early rheumatoid arthritis (RA) is associated with treatment response to synthetic disease-modifying antirheumatic drugs (DMARDs). This prompted us to study the baseline phosphorylation profiles of Janus kinases (JAKs) in blood leukocytes with respect to treatment response in early RA. Methods: Thirty-five DMARD-naive patients with early RA provided blood samples for whole blood flow cytometric determination of phosphorylation of JAKs in CD4(+) and CD8(+) T cells, CD19(+) B cells, and CD14(+) monocytes. Treatment response was determined after 1 year of treatment with synthetic DMARDs, with remission defined as absence of tender and swollen joints and normal erythrocyte sedimentation rate. Exact logistic regression was used to investigate the association of baseline variables with treatment response. Ninety-five percent CIs of means were estimated by bias-corrected bootstrapping. Results: High JAK3 phosphorylation in CD4(+) and CD8(+) T cells, CD19(+) B cells, and CD14(+) monocytes and low JAK2 phosphorylation in CD14(+) monocytes were significantly associated with remission following treatment with synthetic DMARDs. Conclusions: Baseline JAK phosphorylation profile in peripheral blood leukocytes may provide a means to predict treatment response achieved by synthetic DMARDs among patients with early RA.
Subject: Rheumatoid arthritis
Disease-modifying antirheumatic drug
Janus kinases
Phosphorylation
Blood
Leukocyte
Biomarker
SYNOVIAL FIBROBLASTS
CYTOKINE PRODUCTION
AMERICAN-COLLEGE
DISEASE-ACTIVITY
EXPRESSION
METHOTREXATE
THERAPY
CELLS
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Baseline_JAK_phosphorylation_profile.pdf 551.1Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record